Compare Phillips 66 (PSX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Summit Therapeutics Inc — how do they compare? Phillips 66 trades at $281.2 (market cap $112.36B), while Summit Therapeutics Inc trades at $17.27 (market cap $13.71B). The key difference: Phillips 66 is far larger — about 8.2× Summit Therapeutics Inc's market cap, and Phillips 66 pays a 1.8% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and Summit Therapeutics Inc for 16 Days on average.
| PSX | SMMT | |
|---|---|---|
Market Cap | $112.36B | $13.71B |
Volume | 2,374,751 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $281.60 | $26.38 |
52-Week Low | $126.76 | $12.43 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | $128.83B | $13.04B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $283.31, up 4.3% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 16.07, ROE of 24.02%, and consistent earnings beats in recent quarters. Recent news highlights structural refining advantages and AI implementation for operational efficiency, while analyst consensus remains positive with 54% buy ratings.
PSX presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors face risks from volatile energy markets and potential policy changes affecting diesel exports. The current price sits near consensus targets, suggesting balanced near-term upside potential with structural refining strengths supporting long-term value.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
